Quick summary: A new systematic review finds that psychological therapy, particularly cognitive-based approaches, produces meaningful reductions in depressive symptoms in people who have not responded to at least two rounds of antidepressants. The analysis, drawing on 12 clinical trials involving 723 adults, suggests that mindfulness-based cognitive therapy and cognitive behavioural therapy offer genuine benefit even where standard treatments have failed. For clinicians and policymakers, the findings reinforce the case for integrating psychological therapies into care pathways for treatment-resistant depression, while pointing to the need for larger trials and longer follow-up periods to establish which approaches work best and for whom.
For the millions of people living with depression that does not respond to medication, the search for effective treatment can feel exhausting and isolating. A new systematic review and meta-analysis offers some cautious but meaningful encouragement, finding that psychological therapy can produce meaningful improvements in depressive symptoms even in people who have not responded to at least two prior treatments.
The condition, known as treatment-resistant depression, affects a significant proportion of those diagnosed with major depressive disorder. Research suggests that between 30% and 55% of people with depression remain symptomatic after two rounds of antidepressants. For this group, the consequences are severe: poorer quality of life, reduced ability to work or maintain relationships, and a substantially higher risk of suicide compared with those who respond to first-line treatments.
The study, published in the Journal of Personalized Medicine, pooled data from 12 clinical trials involving 723 adults. When the results of all psychotherapy types were combined, researchers found a small to moderate but statistically significant reduction in depressive symptoms in favour of therapy over control conditions.
Shari B. Kaplan, LCSW, integrative mental health clinician at Cannectd Wellness, argues that the issue runs deeper than symptom management. “Complex depression often has roots in unresolved trauma or profound nervous system dysregulation,” she said. “Think of your nervous system as the air-traffic control for all aspects of your health. If it is overwhelmed, standard medications may not work properly because the central nervous system is on overdrive.”
Mindfulness-based cognitive therapy, cognitive behavioural therapy, and cognitive therapy each demonstrated moderate reductions in depressive symptoms when examined separately. These approaches share common elements, including techniques for identifying and challenging negative thought patterns and rumination, which may partly explain why they performed similarly.
Dr Justin Jacques, counsellor and chief operating officer at Human Theory Group, draws on over two decades of clinical experience to support these findings. “CBT and other cognitive-based therapies can be very helpful for those with treatment-resistant depression,” he said. “Our therapy sessions really help clients change their thinking and build tools on how to identify, relate to, and process their thoughts, feelings, and emotions in a more helpful way.”
Kaplan echoes this view, emphasising the importance of treating the whole person. “Mindfulness and cognitive-based therapies are highly effective for complex depression because they address beliefs, thoughts, emotions, behaviours, and the central nervous system,” she said. “Long-term recovery requires moving away from simply masking symptoms to help patients become mindful and present.”
The authors were careful to highlight the limitations of their work. Only 12 studies met the eligibility criteria, and most followed participants only to the end of treatment, leaving the question of long-term effectiveness largely unanswered.
Looking ahead, Dr Jacques points to emerging treatments as potentially transformative. “Psychedelics combined with CBT and other cognitive restructuring tools could be a game changer for those with treatment-resistant depression,” he said. “It is an incredible time to be in this field, as there are many more tools coming into play.”
